Grünenthal and Averitas Pharma announce initiation of Phase III study with QUTENZA® to prepare label extension in the US for the treatment of post-surgical neuropathic pain
- Tuesday, March 30, 2021, 8:37
- PR Newswire
- Add a comment
AACHEN, Germany and MORRISTOWN, N.J., March 30, 2021 /PRNewswire/ — Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc. will conduct a Phase III trial to study the efficacy, safety and tolerability of QUTENZA (capsaicin) 8% topical system in post-surgical…
About the Author
admin has written 20720 stories on this site.